FDA уделит приоритетное внимание рассмотрению ингибитора STAMP аскиминиба компании Novartis для лечения хронического миелоидного лейкоза – drugdiscoverytrends.com
FDA to prioritize review of Novartis STAMP inhibitor asciminib for chronic myeloid leukemia drugdiscoverytrends.com
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
Questions frequentes
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
